- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05848713
Thérapie antithrombotique pour améliorer les complications cliniques de la pneumonie communautaire (ATTACC-CAP)
This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The global incidence of hospitalization due to CAP is high and associated with substantive morbidity and mortality. Thrombotic complications - including venous, arterial, and possibly microvascular - occur commonly in hospitalized patients across many etiologies of CAP. Poor outcomes may be mediated by both inflammatory and thrombotic processes leading to respiratory, cardiac, and other end organ dysfunction. There are currently no established therapies that modify the potentially maladaptive immunothrombosis pathway in CAP.
Therapeutic-dose anticoagulation with heparin reduces disease progression and mortality in non-critically ill patients hospitalized with COVID-19 with an acceptable safety profile. COVID-19 shares pathogenic features, including activation of the inflammatory and coagulation cascades, with other pneumonias. Whether therapeutic-dose heparin confers similar clinical benefits in non-COVID-19 CAP is unknown.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Chantale Pineau
- Numéro de téléphone: 2042353223
- E-mail: attacc.cap@umanitoba.ca
Lieux d'étude
-
-
Espírito Santo
-
Serra, Espírito Santo, Brésil, 29166-828
- Recrutement
- Hospital Estadual Dr. Jayme Santos Neves
-
Contact:
- Marcus Matos, MD
-
Chercheur principal:
- Marcus Matos, MD
-
Vila Velha, Espírito Santo, Brésil
- Recrutement
- Hospital Evangelico de Vila Velha
-
Contact:
- Joao Moraes Junior, MD
-
Chercheur principal:
- Joao Moraes Junior, MD
-
Chercheur principal:
- Guiherme Fonseca, MD
-
-
Estado de Bahia
-
Itabuna, Estado de Bahia, Brésil
- Complété
- Santa Casa de Misericordia de Itabuna
-
-
Federal District
-
Brasília, Federal District, Brésil
- Complété
- Hospital Brasilia
-
Brasília, Federal District, Brésil
- Complété
- Instituto de Cardiologia e Transplantes do Distrito Federal
-
-
Goiás
-
Goiânia, Goiás, Brésil
- Recrutement
- Hospital de Messejana Dr. Carlos Alberto Studart Gomes
-
Contact:
- Sandra Nivea dos Reis Saraiva, MD
-
Chercheur principal:
- Sandra Falcao, MD
-
Goiânia, Goiás, Brésil
- Recrutement
- Hospital Ruy Azeredo
-
Contact:
- Rafael Bastos, MD
-
Chercheur principal:
- Rafael Bastos, MD
-
Goiânia, Goiás, Brésil
- Recrutement
- Instituto Goiano de Oncologia e Hematologia - INGOH
-
Contact:
- Mayler Santos, MD
-
Chercheur principal:
- Mayler Santos, MD
-
-
Mato Grosso do Sul
-
Campo Grande, Mato Grosso do Sul, Brésil
- Recrutement
- Hospital São Julião
-
Contact:
- Maurício Pompílio Pompílio, MD
-
Campo Grande, Mato Grosso do Sul, Brésil
- Recrutement
- Santa Casa de Campo Grande
-
Contact:
- Eduardo Calvoso, MD
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brésil
- Complété
- Hospital Felicio Rocho
-
Belo Horizonte, Minas Gerais, Brésil
- Complété
- NUPEC-Orizonti
-
Belo Horizonte, Minas Gerais, Brésil
- Recrutement
- Santa Casa de Misericórdia de Belo Horizonte
-
Contact:
- Claudio Dornas, MD
-
Uberaba, Minas Gerais, Brésil
- Recrutement
- Hospital das Clínicas da Universidade Federal do Triângulo Mineiro
-
-
Paraná
-
Campo Largo, Paraná, Brésil, 83606-177
- Recrutement
- Hospital do Rocio
-
Contact:
- CESAR DUSILEK, MD
-
Curitiba, Paraná, Brésil
- Recrutement
- Hospital Santa Cruz
-
Contact:
- Marcelo Carneiro, MD
-
Chercheur principal:
- Marcelo Carneiro, MD
-
Curitiba, Paraná, Brésil
- Complété
- PUCPR
-
-
Rio Grande do Sul
-
Lajeado, Rio Grande do Sul, Brésil
- Recrutement
- Hospital Bruno Born
-
Contact:
- Lucas Mallmann, MD
-
Chercheur principal:
- Lucas Mallmann, MD
-
Passo Fundo, Rio Grande do Sul, Brésil
- Recrutement
- Hospital Sao Vicente de Paulo
-
Contact:
- Alexandre Tognon, MD
-
Chercheur principal:
- Alexandre Tognon
-
Porto Alegre, Rio Grande do Sul, Brésil
- Recrutement
- Hospital de Clínicas de Porto Alegre
-
Contact:
- Paulo Dalcin, MD
-
Chercheur principal:
- Paulo Dalcin, MD
-
Santa Maria, Rio Grande do Sul, Brésil
- Complété
- Hospital Universitario de Santa Maria
-
-
Rio de Janeiro
-
Rio de Janeiro, Rio de Janeiro, Brésil
- Recrutement
- Hospital Clementino Fraga Filho - UFRJ
-
Contact:
- Fernanda Mello
-
-
Santa Catarina
-
Criciúma, Santa Catarina, Brésil
- Recrutement
- Hospital Sao Jose
-
Contact:
- Felipe Pizzol, MD
-
Chercheur principal:
- Felipe Pizzol, MD
-
-
South Carolina
-
São José, South Carolina, Brésil
- Complété
- Hospital Regional Homero Miranda Gomes
-
-
São Paulo
-
Botucatu, São Paulo, Brésil
- Recrutement
- UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu
-
Contact:
- Suzana Erico Tanni, MD
-
Chercheur principal:
- Suzana Erico Tanni, MD
-
Bragança Paulista, São Paulo, Brésil
- Recrutement
- Hospital Universitario Sao Francisco na Providencia na Deus
-
Contact:
- Gustavo Mamprin, MD
-
Chercheur principal:
- Gustavo Mamprin, MD
-
Campinas, São Paulo, Brésil
- Recrutement
- IPECC
-
Contact:
- Jose Francisco Kerr Saraiva, MD
-
Chercheur principal:
- Jose Francisco Kerr Saraiva, MD
-
Campinas, São Paulo, Brésil, 13083-190
- Recrutement
- Fundação Centro Médico de Campinas
-
Contact:
- Otavio Coelho, MD
-
Chercheur principal:
- Otavio Coelho, MD
-
Osasco, São Paulo, Brésil
- Recrutement
- CiTen - Centro Hospital Municipal Antonio Giglio
-
Contact:
- Enrico Fortunato, MD
-
Chercheur principal:
- Enrico Fortunato, MD
-
Presidente Prudente, São Paulo, Brésil
- Recrutement
- Hospital Regional de Presidente Prudente
-
Contact:
- Luis Felipe Pires, MD
-
Chercheur principal:
- Luis Felipe Pires, MD
-
Ribeirão Preto, São Paulo, Brésil
- Pas encore de recrutement
- Hospital Estadual de Serrana
-
Contact:
- Marcos Borges, MD
-
Chercheur principal:
- Marcos Borges, MD
-
São Paulo, São Paulo, Brésil, 05403-010
- Recrutement
- HCFMUSP
-
Contact:
- Ludhmila Hajjar, MD
-
Chercheur principal:
- Ludhmila Hajjar, MD
-
São Paulo, São Paulo, Brésil, 02189-010
- Recrutement
- Hospital Nipo-Brasileiro
-
Contact:
- Jose Victor Krasner Schubsky, MD
-
São Paulo, São Paulo, Brésil
- Complété
- Santa Casa de Misericordia de Sao Paulo
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Recrutement
- Foothills Medical Centre - Alberta Health Services
-
Contact:
- Deepa Suryanarayan, MD
- Numéro de téléphone: 4039448167
- E-mail: dsuryana@ucalgary.ca
-
Chercheur principal:
- Deepa Suryanarayan, MD
-
Grande Prairie, Alberta, Canada, T8V 4B1
- Pas encore de recrutement
- Grand Prairie Regional Hospital
-
Contact:
- Tafi Madzimure, MD
-
Chercheur principal:
- Tafi Madzimure, MD
-
-
British Columbia
-
Nanaimo, British Columbia, Canada
- Recrutement
- Nanaimo Regional General Hospital
-
Contact:
- Alistair Teale, MD
-
Chercheur principal:
- Alistair Teale, MD
-
Penticton, British Columbia, Canada
- Pas encore de recrutement
- Penticton Regional Hospital
-
Contact:
- Teresa Rodriguez, MD
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Recrutement
- Vancouver General Hospital
-
Chercheur principal:
- Ted Steiner, MD
-
Contact:
- Ted Steiner, MD
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
- Recrutement
- St. Boniface General Hospital
-
Contact:
- Vi Dao, MD
-
Chercheur principal:
- Terry Wuerz, MD
-
Chercheur principal:
- Vi Dao, MD
-
Winnipeg, Manitoba, Canada, R3A 1R9
- Recrutement
- Health Sciences Center Winnipeg
-
Contact:
- Brett Houstin, MD
-
Winnipeg, Manitoba, Canada
- Recrutement
- Grace General Hospital
-
Contact:
- Sylvain Lother, MD
- E-mail: sylvain.lother@umanitoba.ca
-
Chercheur principal:
- Sylvain Lother, MD
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1C 5S7
- Recrutement
- Memorial University
-
Contact:
- Peter Daley, MD
-
Chercheur principal:
- Peter Daley, MD
-
-
Ontario
-
Greater Sudbury, Ontario, Canada, P3E 2H3
- Recrutement
- Health Sciences North Research Institute
-
Contact:
- Pandma Puranam, MD
-
Chercheur principal:
- Pandma Puranam, MD
-
Greater Sudbury, Ontario, Canada
- Recrutement
- Health Sciences North ResearchInstitute (HSNRI)
-
Contact:
- Pandma Puranam, MD
-
Hamilton, Ontario, Canada
- Recrutement
- Hamilton Health Sciences
-
Contact:
- Alison Fox-Robichaud, MD
-
Chercheur principal:
- Alison Fox-Robichaud, MD
-
Hamilton, Ontario, Canada
- Recrutement
- Hamilton Health Sciences - Juravinski
-
Chercheur principal:
- Dominik Mertz, MD
-
Chercheur principal:
- Bram Rochwerg, MD
-
Contact:
- Bram Rochwerg, MD
-
Markham, Ontario, Canada, L3P 7P3
- Recrutement
- Markham Stouffville Hospital
-
Chercheur principal:
- Paul Lee, MD
-
Contact:
- Paul Lee, MD
-
Chercheur principal:
- Janet Nguyen, MD
-
Ottawa, Ontario, Canada
- Recrutement
- The Ottawa Hospital
-
Contact:
- Lana Castellucci, MD
-
Ottawa, Ontario, Canada
- Recrutement
- Hôpital Montfort
-
Contact:
- Marc Carrier, MD
-
Saint Catherines, Ontario, Canada, L2S 0A9
- Recrutement
- Niagara Health System - St Catharines Site
-
Contact:
- Aidan Findlater, MD
- E-mail: Aidan.Findlater@niagarahealth.on.ca
-
Chercheur principal:
- Aidan Findlater, MD
-
Toronto, Ontario, Canada, M4N 3M5
- Recrutement
- Sunnybrook Health Sciences Centre
-
Contact:
- Jonathan Zipursky, MD
-
Chercheur principal:
- Jonathan Zipursky, MD
-
Toronto, Ontario, Canada
- Pas encore de recrutement
- St. Michael's Hospital
-
Contact:
- Michael Colacci, MD
-
-
Quebec
-
Montreal, Quebec, Canada
- Recrutement
- Jewish General Hospital
-
Contact:
- Susan Khan, MD
-
Contact:
- Vicky Tagalakis, MD
-
Montreal, Quebec, Canada, H4A3J1
- Recrutement
- McGill University Health Centre
-
Contact:
- Emily Gibson McDonald, MD, MSc
-
Montreal, Quebec, Canada
- Recrutement
- Centre Hospitalier de l'université de Montréal (CHUM)
-
Contact:
- Emmanuelle Duceppe, MD
-
Québec, Quebec, Canada
- Recrutement
- CHU de Quebec-University Laval
-
Contact:
- Alexis Turgeon, MD, MSc
-
Québec, Quebec, Canada
- Recrutement
- Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)
-
Contact:
- Francois Lallouche, MD
-
Sherbrooke, Quebec, Canada
- Recrutement
- Centre Hospitalier Universitaire de Sherbrooke
-
Chercheur principal:
- Francois Lamontagne, MD
-
Contact:
- Francois Lamontagne, MD
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4P 0W5
- Recrutement
- Regina General Hospital
-
Chercheur principal:
- Payam Dehghani, MD
-
Contact:
- Payam Dehghani, MD
-
Saskatoon, Saskatchewan, Canada
- Pas encore de recrutement
- University of Saskatchewan
-
Contact:
- Geroffrey Shumailak, MD
-
-
-
-
Mexico City
-
Mexico City, Mexico City, Mexique
- Recrutement
- Hospital General Regional 1. Carlos MacGregor Sánchez Navarro
-
-
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- University of Chicago
-
Contact:
- Jonathan Paul, MD
-
-
Louisiana
-
Jefferson, Louisiana, États-Unis, 70121
- Recrutement
- Ochsner Clinic
-
Contact:
- Derek Vondehaar, MD
-
-
Maine
-
Portland, Maine, États-Unis, 04102
- Recrutement
- Maine Medical Centre
-
Contact:
- Daniel Meyer, MD
-
Chercheur principal:
- Daniel Meyer, MD
-
-
Michigan
-
Dearborn, Michigan, États-Unis, 48128
- Complété
- Henry Ford Health System
-
-
New Jersey
-
Camden, New Jersey, États-Unis, 08103
- Recrutement
- Cooper University Health Care
-
Contact:
- Adam Green, MD
-
Chercheur principal:
- Adam Green, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Recrutement
- Medical College of Wisconsin
-
Contact:
- Alisha Sharma, MD
-
Chercheur principal:
- Alisha Sharma, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Patients ≥18 years of age
-
Admitted to hospital for a suspected or confirmed diagnosis of CAP defined by:
- Radiographic evidence of new or worsening infiltrate
- One or more of the following signs and/or symptoms of lower respiratory tract infection
i. New or increased cough or sputum production ii. Fever of > 37.8C or temperature < 36C iii. WBC > 11 x 109/L or < 4 x 109/L c. The primary diagnosis is believed to be CAP as per the attending physician
-
Requires supplemental oxygen to treat hypoxemia (or requires an increased level of supplemental oxygen if on chronic oxygen therapy)
-
Hospital admission anticipated to last ≥72 hours from randomization
Exclusion Criteria:
-
Suspected or confirmed active COVID-19 infection
-
Hospital admission for >72 hours prior to randomization
-
Patients receiving non-invasive or invasive ventilation, vasopressors, or extracorporeal life support (ECLS) within an ICU at the time of enrollment
-
Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization
-
Patients for whom the intent is to not use pharmacologic thromboprophylaxis
-
Patients with an independent indication for therapeutic-dose anticoagulation
-
Patients with a contraindication to therapeutic-dose anticoagulation, including:
- Non-traumatic bleeding that requires medical evaluation or hospitalization within 30 days prior to CAP hospital admission
- History of an inherited or acquired bleeding disorder
- Cerebral aneurysm or mass lesions of the central nervous system
- Ischemic stroke within 3 months of hospital admission
- Gastrointestinal bleeding within 3 months of hospital admission
- Platelet count <50 x109/L OR INR >2.0 OR hemoglobin <80 g/L at the time of screening
- Other physician-perceived contraindications to therapeutic anticoagulation
-
History of heparin induced thrombocytopenia (HIT) or other heparin allergy
-
Current or recent (within 7 days of screening) use of dual anti-platelet inhibitors (For example; Aspirin + one of the following; clopidogrel, ticagrelor, prasugrel)
-
Patients in whom imminent death is anticipated
-
Anticipated transfer to another hospital that is not a study site within 72 hours of randomization
-
Enrollment in other interventional trials related to anticoagulation or antiplatelet therapy during current hospitalization
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Therapeutic-Dose Heparin
Participants randomized to the investigational arm will receive a pragmatic strategy of therapeutic-dose low molecular-weight heparin (LMWH) or unfractionated heparin (UFH) administered daily for up to 14 days or until hospital discharge, whichever occurs first. Participants should start receiving study drug as soon as possible following randomization. |
Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient. Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement. |
|
Aucune intervention: Usual Care
Participants randomized to the control arm will receive usual care thromboprophylactic dose anticoagulation according to local practice. To ensure adequate separation between the study groups, the dose of heparin/LMWH used in the usual care arm should not equal more than half of the approved therapeutic dose for that agent according to local VTE treatment protocols. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Ordinal endpoint reflecting survival
Délai: 30 days
|
Survival to hospital discharge without ICU-level organ support. Organ support is defined as receipt of high flow nasal oxygen, invasive or non-invasive mechanical ventilation, vasopressor/inotropic therapy, or extracorporeal life support (ECLS) within an ICU. This outcome reflects disease progression to ICU-level organ failure or the worst possible outcome (death). It was chosen because of its importance to patients, clinicians, and other stakeholders. Given the limited number of ICU beds, reducing the burden of critical illness has important health system capacity implications. |
30 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mortalité toutes causes
Délai: 30 jours, 90 jours et 180 jours
|
30 jours, 90 jours et 180 jours
|
|
|
Bleeding events
Délai: 14 days
|
Number of participants with major bleeds as defined by the ISTH definition. |
14 days
|
|
HIT events
Délai: 14 days
|
Number of participants with laboratory confirmed heparin induced thrombocytopenia (HIT) |
14 days
|
|
Thrombotic events
Délai: 30 days and 90 days
|
Number of participants with deep vein thrombosis, pulmonary embolism, systemic arterial thromboembolism, myocardial infarction, or ischemic stroke |
30 days and 90 days
|
|
Invasive mechanical ventilation
Délai: 30 days
|
Ordered categorical endpoint with three possible outcomes based on the worst status of each patient through day 30 following randomization |
30 days
|
|
Hospital-free days
Délai: 30 days, 90 days, and 180 days
|
Days alive outside hospital |
30 days, 90 days, and 180 days
|
|
Health related quality of life
Délai: 30 days, 90 days, and 180 days
|
Using the EQ-5D-5L instrument |
30 days, 90 days, and 180 days
|
|
Health related quality of life
Délai: 30 days, 90 days, and 180 days
|
Using the Clinical Frailty Scale instrument |
30 days, 90 days, and 180 days
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Patrick Lawler, MD, University Health Network and McGill University
- Chercheur principal: Sylvain Lother, MD, University of Manitoba
- Chercheur principal: Alexis Turgeon, MD, L'Universite Laval
- Chercheur principal: Ryan Zarychanski, MD, University of Manitoba
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ATTACC-CAP
- OZM-129 (Autre identifiant: Ozmosis Research Inc.)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .